^
    Back
    Association details:
    Biomarker:MAP3K1 mutation
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nature
    Title:

    PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

    Excerpt:
    Interestingly, PDXs with MAP3K1 alterations were more sensitive to alpelisib (one-tailed p = 0.001), but not buparlisib.
    DOI:
    10.1038/s41523-019-0126-6